Pain treatment and surgical solutions leader Bioventus has agreed to contract with Aetna Medicare Advantage plans beginning Jan. 1, 2024.
Over 3 million Aetna Medicare Advantage plan members nationwide will have access to Durolane, a single-injection hyaluronic acid-based joint-fluid treatment for patients with knee osteoarthritis pain.
Durolane is now one of two single-injection HA products under contract, according to a Dec. 6 press release from Bioventus.